Research

Hormonal

Treatment with semaglutide 2.4 mg for 12 months significantly reduces body weight and improves cardiometabolic risk factors (blood pressure, lipids, HbA1c) in adults with obesity or overweight compared to no obesity medication treatment.

If you have obesity or overweight with related health issues, semaglutide 2.4 mg taken once weekly for a year can lead to significant weight loss (around 15%) and improvements in blood pressure, cholesterol, and blood sugar compared to not using obesity medication. It requires a gradual dose increase to 2.4 mg and should be combined with diet and exercise.

GoodSupportsHIGH confidence
In this real-world study, adults with obesity or overweight treated with semaglutide 2.4 mg had greater reductions in weight and improvements in cardiometabolic risk factors compared with patients not treated with OM at 12 months.
Aleksandrina Ruseva et al. · Advances in Therapy · 2025

Why this rating

Large-scale real-world retrospective cohort study with propensity score matching, though not a randomized controlled trial.

Source

Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study

Aleksandrina Ruseva et al. · Advances in Therapy · 2025

DOI 10.1007/s12325-025-03320-6

cohort · n=44285Cited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →